PDE5A and prostate cancer: They showed that in DU-145 and PC-3 prostate cancer cell lines PDE5 and PDE11 were responsible for cGMP-specific PDE activity and that chemical inhibition of PDE5 with zaprinast was associated with reduced hypoxia-induced resistance to doxorubicin in vitro and reduced tumour growth in vivo.